Page 1

AbCellera NEWS RELEASE AbCellera Reports Q2 2021 Business Results 8/12/2021 ● ● 2215 Yukon St. Vancouver , BC Canada , V5Y OA1 T 1. 604.559.9005 abcellera.com Total revenue of $ 28 million , up from $ 11 million in Q2 2020 Total programs under contract of 138 , up 82 % from Q2 2020 Net loss of ( $ 0.01 ) per share ( basic and diluted ) compared to net earnings of $ 0.03 per share ( basic and diluted ) in Q2 2020 VANCOUVER , British Columbia -- ( BUSINESS WIRE ) -- AbCellera ( Nasdaq : ABCL ) , a technology company with a centralized operating system for next - generation antibody discovery , today announced financial results for the second quarter of 2021. All financial information in this press release is reported in U.S. dollars , unless otherwise indicated . " This quarter we delivered strong growth across key performance indicators related to our partnership business , including new programs under contract , program starts , and new molecules in the clinic , " said Carl Hansen , Ph.D. , CEO of AbCellera . " We continue to drive value in our partnership business by building a diversified portfolio of potential future royalty streams across a broad range of indications and antibody modalities . We are also extending this model to create opportunities to deepen our position with assets that can provide economics similar to an internal pipeline while staying focused on preclinical discovery and development . " Q2 2021 Business Summary Earned $ 27.6 million in total revenue , including $ 22.2 million in milestones and royalties . Incurred net loss of $ 2.3 million , compared to generating net earnings of $ 6.7 million in Q2 2020 . Added 19 programs under contract with four new partners , resulting in a cumulative total of 138 programs under contract with 33 different partners . • Started discovery on six programs , bringing the cumulative number of program starts to 60 . 1